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ALDH1A3 Mutations Cause Recessive
Anophthalmia and Microphthalmia
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Eduardo Silva,5 Margaux Serey,1 Vale´rie Serre,1,6 Xavier Ge´rard,1 Clarisse Baumann,7 Ghislaine Plessis,8
Be´ne´dicte Demeer,9 Lionel Bre´tillon,10 Christine Bole,11 Patrick Nitschke,12 Arnold Munnich,1
Stanislas Lyonnet,1 Patrick Calvas,2,3 Josseline Kaplan,1,* Nicola Ragge,13,14 and Jean-Michel Rozet1,*
Anophthalmia and microphthalmia (A/M) are early-eye-development anomalies resulting in absent or small ocular globes, respectively.
A/M anomalies occur in syndromic or nonsyndromic forms. They are genetically heterogeneous, some mutations in some genes being
responsible for both anophthalmia and microphthalmia. Using a combination of homozygosity mapping, exome sequencing, and
Sanger sequencing, we identified homozygosity for one splice-site and two missense mutations in the gene encoding the A3 isoform
of the aldehyde dehydrogenase 1 (ALDH1A3) in three consanguineous families segregating A/M with occasional orbital cystic, neuro-
logical, and cardiac anomalies. ALDH1A3 is a key enzyme in the formation of a retinoic acid gradient along the dorso-ventral axis during
early eye development. Transitory expression of mutant ALDH1A3 open reading frames showed that both missense mutations reduce
the accumulation of the enzyme, potentially leading to altered retinoic acid synthesis. Although the role of retinoic acid signaling in eye
development is well established, our findings provide genetic evidence of a direct link between retinoic-acid-synthesis dysfunction and
early-eye-development anomalies in humans.Anophthalmia and microphthalmia (A/M) are rare errors
of eye development (with a combined prevalence of
3:100,000 to 30:100,000).1 Whereas true anophthalmia
refers to the histological absence of ocular tissue in the
orbit, microphthalmia ranges from extreme cases with
only tiny or no visible remnants of globe in the orbit
(also called ‘‘clinical anophthalmia’’) to simple micro-
phthalmia with structurally normal small eyes (axial
length at least 2 SD below the mean for an individual of
that age).1 A/M may affect one or both eyes. Both errors
are associated with systemic anomalies in at least 50% of
individuals,2 a large proportion of such individuals pre-
senting with defined syndromes.1,3–5 Learning difficulties
are described in one-fifth of individuals with A/M and/or
coloboma.6 This frequency is probably higher in individ-
uals with A/Mwhen isolated colobomia cases are excluded.
Both genetic and environmental factors contribute to A/M.
Monogenic A/M is inherited as autosomal-dominant (AD),
autosomal-recessive (AR), or X-linked traits. Both AD and
AR forms are characterized by clinical and genetic hetero-
geneity.3 To date, mutations in genes critical for normal
eye development have been identified in 20%–40% of
A/M cases, some genes being involved in simple, complex,
and syndromic A/M.7–10 With the exception of SOX2
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The Americmutations in other genes are, individually, uncommon
causes of the disease.3,10–12
Using a combination of the Affymetrix GeneChip
HumanMapping 10K 2.0 Array andmicrosatellite markers,
we performed homozygosity mapping in a multiplex
inbred Pakistani pedigree with multiple loops of consan-
guinity (Figure 1) in whom Sanger sequencing failed to
detect mutations in GDF6 (MIM 601147), FOXE3 (MIM
601094), OTX2 (IM 600037), PAX6 (MIM 607108), RAX
(MIM 601881), SOX2 (MIM 184429), and VSX2 (CHX10,
[MIM 142993]). Informed consent was obtained from
each individual participating in this study, which was
approved by Le Comite´ de Protection des Personnes Ile
de France II or by the Cambridgeshire 1 Multicenter
Research Ethics Committee (04/Q0104/129). Considering
that A/M-causing mutations are rare, we assumed that
affected individuals of the two available nuclear families
(IV1, IV4, and IV5; Figure 1) were most likely homozygous
for the same disease-causing mutation and surrounding
SNP markers. This strategy defined three regions with
LOD scores R 3 (2p24.2–p24.1, 5.5Mb; 8q24, 0.7Mb; and
15q26.3, 3.8Mb) and one region with a LOD score close
to 3 (4p14–p11, 10.1Mb) (Figure 1A). Analysis of highly
informative microsatellite markers in each candidate
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Figure 1. Linkage Analysis, Pedigree, and Segregation Analysis in A/M Families with Homozygous ALDH1A3 Mutations
(A) Full parametric linkage analysis of family 1 using a combination of Affymetrix GeneChip Human Mapping 10K 2.0 Arrays.
Parametric LOD scores were calculated with the MERLIN software program.
(B) Pedigree, haplotype, and/or segregation analyses of ALDH1A3 mutations in the three A/M families. The positions of microsatellite
markers of the 15q26.3 region based on hg19 assembly of the human genome were obtained from the: Human (Homo sapiens) Genome
Browser Gateway at UCSC. ml, c.265C>T (p.Arg89Cys); m2, c.1477G>C (p.Ala493Pro); m3, c.475þ1G>T; þ, wild-type allele.chromosomes 2p24, 8q24, and 4p14–p11 resulted from
uninformative SNP markers (data not shown). Conversely,
homozygosity for informative markers of the 15q26.3
locus was confirmed (Figure 1B).
The critical interval on 15q26.3 spanned 3.8 Mb and
contained 31 genes. To identify the disease-causing muta-
tion, we subjected the DNA of the index case, IV1, to
whole-exome sequencing by using the SureSelectXT
Human All Exon V3 50 Mb target-enrichment kit (Agilent
Technologies, Massy, France) in accordance with the
manufacturer’s recommendations. Each genomic DNA
fragment was sequenced with the use of the paired-end
strategy and an average read length of 75 bases (Illumina
HISEQ, Illumina, San Diego, CA, USA). Image analysis
and base calling were performed with the Illumina
Sequence Control Software (SCS) with Real Time Analysis
(RTA) version 1.9 and default parameters were used.
Sequences were aligned to the human genome reference
sequence (hg19 assembly), and SNPs were called on the
basis of allele calls and read depth with the use of the
CASAVA pipeline (Consensus Assessment of Sequence
and Variation 1.8, Illumina). Genetic variation annotation266 The American Journal of Human Genetics 92, 265–270, Februarywas performed with an in-house pipeline (Plateforme
Bioinformatique Paris Descartes, Paris, France).
Considering that A/M-causing mutations are
uncommon, we searched for homozygous variants absent
in the dbSNP132, Exome Variant Server, 1000 Genomes,
and in-house databases or with allelic frequencies <0.01.
We found no homozygosity for consensus splice-site
changes, nonsense mutations, or insertions or deletions
in coding regions upon whole-genome analysis. We subse-
quently selected nonsynonymous changes predicted to be
‘‘damaging’’ or ‘‘possibly damaging’’ using the Polyphen
and SIFT programs available through our in-house analysis
pipeline. This led to the selection of 28 variants in 27
genes. The only gene mapping in the 3.8 Mb interval
on chromosome 15q26.3, ALDH1A3 (NM_000693.2
[MIM600463]), harbored a homozygote missense muta-
tion, c.265C>T (p.Arg89Cys) (Table S1, available online).
The mutation was confirmed by Sanger sequencing, and
familial analysis confirmed the biparental transmission of
the mutation and segregation with the disease (Figure 1).
ALDH1A3 encodes a retinaldehyde dehydrogenase
(ALDH1A3; also referred to as RALDH1A3, RALDH3, or7, 2013
ADLH6) involved in retinoic acid synthesis through the
oxidation of retinaldehyde. It plays a pivotal role in
retinoic acid signaling in eye development.13–17 Thus,
ALDH1A3 was regarded a strong candidate gene by virtue
of both its localization and its function.
We performed Sanger sequencing of all 13 exons and the
intron-exon boundaries of ALDH1A3 (Table S2) in a series
of 28 additional A/M index individuals born to consan-
guineous parents with no mutation in GDF6, FOXE3,
OTX2, PAX6, RAX, SOX2, or VSX2. We identified homozy-
gous ALDH1A3 mutations in 2 of 28 simplex individuals
(Figure 1). Thefirst simplex individual, a girl born toTurkish
parents, harbored a homozygous missense mutation,
c.1477G>C (p.Ala493Pro) (IV1, family 2). The second indi-
vidual, a girl born toMoroccanparents,harboredahomozy-
gous splice-sitemutation, c.475þ1G>T (II3, family 3). Bipa-
rental transmission was confirmed in the two families.
The threemutations were absent in the SNP databases, in
the Exome Variant Server, and in 200 control chromo-
somes. Themutationswere analyzedwithAlamutMutation
Interpretation software, a decision-support system for
mutation interpretation based on Align DGVD, Polyphen-
2, SIFT, SpliceSiteFinder-like, MaxEntScan, NNSPLICE,
and Human Splicing Finder. The c.475þ1G>T mutation is
predicted to abolish the splice-donor site of intron 4. This
is expected to result in an in-frame skipping of exon 5,
which contributes to the nicotinamide adenine dinucleo-
tide (NAD) binding pocket (exon 5 codes for residues
159–179; NAD binding pocket: residues 8–135 and 159–
170; Protein Data Bank [PDB] 1BXS). The c.265C>T
(p.Arg89Cys) mutation affects an amino acid conserved
from human to worm and in the ALDH1A1 and ALDH1A2
paralogs. The c.1477G>C (p.Ala493Pro) mutation changes
a residue conserved from human to frog. In fish, fly, and
C. elegans, the p.Ala493 residue is replaced by a leucine or
a glycine residue. The replacement of the positively charged
p.Arg89 by a cysteine residue and the replacement of
p.Ala495 by a proline residue were both predicted to be
deleterious by the Alamut Interpretation software.
The three-dimensional structure of the tetrameric
human ALDH1A3 (residues 20–511; Figure S1A) was
modeled by comparative protein modeling methods and
energy minimization with the use of the Swiss-Model
program in the automated mode.18–20 The 2.35 A˚ coordi-
nate set for the tetrameric sheep liver class 1 aldehyde
dehydrogenase with bound NAD (PDB code 1BXS) was
used as a template for modeling the human ALDH1A3
protein (71.3% sequence identity). Swiss-PdbViewer 3.7
was used for structural insight into ALDH1A3 substitu-
tions. The p.Arg89 residue is located between two helixes
in a conserved loop of the NAD binding domain. Molec-
ular modeling of the wild-type (WT) protein suggests
that the p.Arg89 amino acid is involved in the stabilization
of the tetramer through its interaction with p.Asn511
residue at a distance of 5 A˚ in another subunit (Figure S1B).
This latter residue is located in a loop connecting the two
b sheets of the monomeric oligomerization domain.The AmericThus, the p.Arg89Cys substitution most likely affects the
stability of the tetramer. The p.Ala493 residue is located
in a small helix between two b sheets involved in the olig-
omerization domain of the enzyme (Figure S1C). The
introduction of a proline at position 493 in the helix is
expected to introduce an elbow, leading to an incorrect
position of the two b sheets relative to each other and
hampering the tetramerization of the enzyme.
Using site-directed mutagenesis (QuikChange II Site-
Directed Mutagenesis Kit, Agilent), we introduced the
c.265C>T (p.Arg89Cys) and c.1477G>C (p.Ala493Pro)
A/M mutations into a pCMV6-entry eukaryote expression
vector that encodes the full ALDH1A3 open reading frame
and is fused to c-Myc (Origen, Rockville, MD, USA). We
also generated a construct harboring a mutation that
affected the p.Trp180 (c.538T>G; p.Trp180Gly) residue.
This residue corresponds to the p.Trp168 amino acid,
which is directly involved in the fixation of NAD in the
sheep ALDH1 and does not interfere with the oligomeri-
zation of the protein. Primers used for mutagenesis are
shown in Table S3. We assessed the effect of the ALDH1A3
substitutions on mRNA and protein levels in human
embryonic kidney cells (HEK293 cells) transiently cotrans-
fected with WT or mutant ALDH1A3 constructs, and
pCGA-GFP (Addgene, Cambridge, MA, USA) to normalize
the data. RT-qPCR using primers specific to the c-Myc
tag and the GFP normalizer (Table S4) showed no signifi-
cant difference in expression between WT and mutant
ALDH1A3 mRNA (Figure S2). Immunoblot analysis re-
vealed that the c-Myc-tagged ALDH1A3 p.Arg89Cys and
p.Ala493Pro mutant protein levels were strongly reduced
compared to the WT and p.Trp180Gly mutant proteins,
suggesting that the p.Arg89Cys and p.Ala493Pro mutant
proteins might be unstable and subject to proteasomal
degradation, leading to an absence or low level of high-
molecular-weight complexes (Figure 2).
Together, our findings suggest that the synthesis of
retinoic acid by ALDH1A3 is impaired in the affected
individuals (n ¼ 5) of the three families who consistently
presented severe bilateral clinical anophthalmia (extreme
microphthalmia with no visible ocular structure). In family
1, the A/M index individual (IV1) was born after full-term
normal delivery and was in the 2nd centile for weight
(2.59 kg), 3rd centile for length (46.5 cm), and 10th centile
for head circumference (33.5 cm). She exhibited small
optic nerves and a small optic chiasm upon a cerebral
MRI at 1 week of age. Autism was diagnosed at the age
of 3 years. She has two healthy sisters. Her mother’s last
pregnancy before the study was terminated at 23 weeks
of gestation after ultrasonography detection of apparent
bilateral anophthalmia with normal brain structures
(IV4) detected on ultrasonography. Her maternal cousin
(IV5) was born at 34 weeks of gestation by Caesarian
section and had a birth weight of 2 kg. He had severe bilat-
eral microphthalmia with cysts (a rudimentary globe
on the left and a grossly abnormal globe associated with
a cyst on the right), moderate pulmonary and supravalvaran Journal of Human Genetics 92, 265–270, February 7, 2013 267
Figure 2. Immunoblot Analysis of Mutant and Wild-Type
ALDH1A3 Proteins
HEK293 cells were transfected with pCMV6-Entry-ALDH1A3-
WT-cMyc, pCMV6-Entry-ALDH1A3-Arg89CYS-aMyc, pCMV6-
Entry-ALDH1A3-Trp180Gly-cMyc, and pCMV6-Entry-ALDH1A3-
ALA493PRO-cMyc plasmids, respectively. The pCAG-GFP plasmid
was systematically cotransfected with the pCMV6-Entry-
ALDH1A3 constructs. Untransfected (UnT) cells served as con-
trols. Total proteins were extracted and run (50 mg) on a NuPAGE
4%–12% Bis-TrisGel (Life Technologies, Cergy Pontoise, France).
c-Myc-tagged proteins and GFP were detected with the use of
mouse anti-cMyc (1:1,000, Santa Cruz, San Diego, CA, USA)
and mouse anti-GFP (1:1,000, Roche, Meylan, France) primary
antibodies, respectively, and with rabbit anti-mouse IgG-HRP
(2 mg/ml, 1:5,000; Abcam, Paris, France) as a secondary antibody.
Immunoblots were revealed with the use of SuperSignalWest Dura
Extended Duration Substrate (Thermo Scientific, Courtaboeuf,
France) and the Chemidoc XRSþ Imaging System (Bio-Rad,
Marnes-la-Coquette, France). Immunoblot images were acquired
and analyzed with the Image Lab software 3.0.1 build 18 (Bio-
Rad). Transfections and immunoblots were performed in tripli-
cate. The figure shows the result of one experiment. A drastic
reduction in the amount of the p.Arg89Cys (p.89Cys) and
p.Ala493Pro (p.493Pro) mutant proteins is shown as compared
to the wild-type (WT) and p.Trp180Gly (p.180Gly) mutant
proteins.pulmonary stenosis, and a moderately sized atrial septal
defect. His growth progressed along the 2nd–9th centile
for weight and length and 0.4th centile for head circumfer-
ence. At the age of 4 years, he has a possible diagnosis of
autism. The proband in family 2 (IV1) has left and extreme
right microphthalmia. She had no other health problems
and displays normal intelligence. A review of the family’s
medical history revealed that a maternal uncle died at
the age of 1 month with bilateral clinical anophthalmia,
but we were unable to obtain additional clinical details.
Finally, the proband in family 3, who had a homozygous
c.475þ1G>T mutation was born after a full term and
normal delivery and had a birth weight of 3.5 kg (II3;
family 3). She presented with severe right microphthalmia
and severe left microphthalmia with cyst. An MRI showed
dysplastic globes, a hypoplastic chiasm and optic nerves,
and a normal remainder of the brain. She had no other
health problems and displays normal intelligence.
In themouse, Aldh1a3, along withAldh1a1 andAldh1a2,
contributes to the synthesis of retinoic acid, which
functions as ligand for nuclear receptors that directly
regulate gene expression crucial for embryonic eye devel-268 The American Journal of Human Genetics 92, 265–270, Februaryopment.16,17 Aldh1a1, Aldh1a2, and Aldh1a3 are expressed
with unique, nonoverlapping, spatiotemporal patterns
in embryonic eyes, leading to tissue- and time-restricted
retinoic acid synthesis during development.16,17 ALDH1A3
is a key enzyme in the formation of a retinoic acid gradient
along the dorso-ventral axis during early eye development.
It is required for the complete invagination of the ventral
optic cup and closure of the choroid fissure.15–17,21,22
It also contributes to correct axonal projections of retinal
cells into the brain.21,22 Interestingly, the phenotype of
A/M individuals with ALDH1A3 mutations is consistent
with abnormal closures of the choroid fissure and
abnormal optic nerve development. Indeed, evidence of
cysts in at least two individuals suggests that globe induc-
tion—and probably invagination—is present, whereas
closure of the choroid fissure may be lacking. In addition,
available MRIs showed hypoplastic optic nerves (n ¼ 2).
In addition to being a key player in the developing
sensory neuroepithelia of the eye, in the mouse, Aldh1a3
plays a role in the development of the nose and ear and
in discrete sites within the CNS.16,17 However, knockout
of Aldh1a3 causes malformations restricted to ocular and
nasal regions.21,22 Aldh1a3/ mutant embryos begin the
process of optic cup formation, but they exhibit ventral
retina shortening associated with lens rotation and persis-
tence of primary vitreous.16,21 In addition, the knockout
causes choanal atresia, which is responsible for respiratory
distress and the death of Aldh1a3/ mutants at birth.21
Individuals homozygous for ALDH1A3 mutations had
ocular malformations but no nasal defects. Unlike the
Aldh1a3 knockout mouse, the affected individuals of the
three families harbor mutations expected to result in
the production of mutant proteins. We cannot exclude
the possibility that the complete loss of function of both
ALDH1A3 alleles is lethal in humans.
Two out of the four living affected individuals had
autism (IV1 and IV5; family 1). The available cerebral
MRI of individual IV1 revealed normal cerebellar and cere-
bral features. Autism and intellectual disability are not
infrequent features in individuals affected with A/M.6
However, given that two A/M individuals had normal
intelligence, autism may be unrelated to altered ALDH1A3
function in the CNS. Similarly, it is difficult to decide
whether the cardiac anomalies noted in an individual
(IV5, family 1) are caused by ALDH1A3 mutations.
Nevertheless, it is worth remembering that extraocular
anomalies are not uncommon in A/M and that environ-
mental or epigenetic factors have been proposed to explain
that some genes are involved in variable phenotypes.12
Additional studies will hopefully allow a more accurate
clinical definition of A/M caused by ALDH1A3 mutations.
In summary, we report that mutations in ALDH1A3
cause bilateral severe microphthalmia, possibly in associa-
tion with heart anomalies and autism. Interestingly, the
role of retinoic acid synthesis from vitamin A in eye
development is well established. Yet, the deciphering of
the genetic causes underlying A/M in humans has resulted7, 2013
in the identification of a number of master control genes
for the growth and development of eyes, downstream of
retinoic acid signaling. The previous example of a direct
link between vitamin A deficiency and severe hereditary
developmental eye defect in humans is STRA6 [MIM
610745], the gene that encodes the membrane receptor
for retinol-binding protein, whichmediates cellular uptake
of vitamin A,23 and mutations in this gene can cause
nonsyndromic and syndromic A/M.8,9 Our data provide
evidence of a direct link between retinoic acid synthesis
dysfunction and eye anomalies in humans. Finally, consid-
ering that eye defects in mouse aldh1a mutants can be
rescued by maternal dietary retinoic acid supplemen-
tation,22 this raises the possibility of using this strategy
to prevent A/M in conceptus that harbor ALDH1A3
mutations.Supplemental Data
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